Cargando…

Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials

BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. In this study, we intend to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Pei-Wen, Hsieh, Kun-Yi, Chen, Kuan-Yu, Hsu, Chin-Wang, Bai, Chyi-Huey, Chen, Chiehfeng, Hsu, Yuan-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808552/
https://www.ncbi.nlm.nih.gov/pubmed/31644605
http://dx.doi.org/10.1371/journal.pone.0224285
_version_ 1783461773847822336
author Chi, Pei-Wen
Hsieh, Kun-Yi
Chen, Kuan-Yu
Hsu, Chin-Wang
Bai, Chyi-Huey
Chen, Chiehfeng
Hsu, Yuan-Pin
author_facet Chi, Pei-Wen
Hsieh, Kun-Yi
Chen, Kuan-Yu
Hsu, Chin-Wang
Bai, Chyi-Huey
Chen, Chiehfeng
Hsu, Yuan-Pin
author_sort Chi, Pei-Wen
collection PubMed
description BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. In this study, we intend to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of migraines. METHOD: PubMed, EMBASE, Cochrane library, and Scopus databases were searched from their inceptions to November 2018. Randomized controlled studies investigating the efficacy of intranasal lidocaine compared with a placebo or an active comparator were selected. Two reviewers independently extracted and synthesized data using a random-effects model. The primary outcome was pain intensity. The secondary outcomes were success rate, the need for rescue medicine, and relapse occurrences. We registered the study at PROSPERO with an ID of CRD42018116226. RESULTS: Six studies (n = 613) were eligible for the meta-analysis. Overall, the results revealed that the study population who was administered intranasal lidocaine had a lower pain intensity at 5 min (standardized mean difference (SMD) = -0.61; 95% CI = -1.04 to -0.19) and 15 min (SMD = -0.72; 95% CI = -1.14 to -0.19), had a higher success rate (RR = 3.55; 95% CI: 1.89 to 6.64) and a less frequent need for rescue medicine (RR = 0.51; 95% CI = 0.36 to 0.72) than the control group. These beneficial effects were not observed when an antiemetic was administered. Furthermore, intranasal lidocaine use had no significant influence on the relapse rate (RR = 0.89; 95% CI = 0.51–1.56), regardless of the use of antiemetics. Using lidocaine caused local irritation in up to 49.4% of the patients in one report but did not cause major adverse events. CONCLUSION: Intranasal lidocaine can be considered a useful option for patients with an acute migraine. It yields a high success rate, a low pain intensity, an infrequent need for rescue medicine, and tolerable adverse events. The administration of antiemetics is an important confounding factor.
format Online
Article
Text
id pubmed-6808552
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-68085522019-11-02 Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials Chi, Pei-Wen Hsieh, Kun-Yi Chen, Kuan-Yu Hsu, Chin-Wang Bai, Chyi-Huey Chen, Chiehfeng Hsu, Yuan-Pin PLoS One Research Article BACKGROUND: Intranasal lidocaine has been shown to be effective in treating patients with acute migraines; however, its efficacy is still controversial. In this study, we intend to assess the efficacy and safety of intranasal lidocaine compared with a placebo or an active comparator for the treatment of migraines. METHOD: PubMed, EMBASE, Cochrane library, and Scopus databases were searched from their inceptions to November 2018. Randomized controlled studies investigating the efficacy of intranasal lidocaine compared with a placebo or an active comparator were selected. Two reviewers independently extracted and synthesized data using a random-effects model. The primary outcome was pain intensity. The secondary outcomes were success rate, the need for rescue medicine, and relapse occurrences. We registered the study at PROSPERO with an ID of CRD42018116226. RESULTS: Six studies (n = 613) were eligible for the meta-analysis. Overall, the results revealed that the study population who was administered intranasal lidocaine had a lower pain intensity at 5 min (standardized mean difference (SMD) = -0.61; 95% CI = -1.04 to -0.19) and 15 min (SMD = -0.72; 95% CI = -1.14 to -0.19), had a higher success rate (RR = 3.55; 95% CI: 1.89 to 6.64) and a less frequent need for rescue medicine (RR = 0.51; 95% CI = 0.36 to 0.72) than the control group. These beneficial effects were not observed when an antiemetic was administered. Furthermore, intranasal lidocaine use had no significant influence on the relapse rate (RR = 0.89; 95% CI = 0.51–1.56), regardless of the use of antiemetics. Using lidocaine caused local irritation in up to 49.4% of the patients in one report but did not cause major adverse events. CONCLUSION: Intranasal lidocaine can be considered a useful option for patients with an acute migraine. It yields a high success rate, a low pain intensity, an infrequent need for rescue medicine, and tolerable adverse events. The administration of antiemetics is an important confounding factor. Public Library of Science 2019-10-23 /pmc/articles/PMC6808552/ /pubmed/31644605 http://dx.doi.org/10.1371/journal.pone.0224285 Text en © 2019 Chi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Chi, Pei-Wen
Hsieh, Kun-Yi
Chen, Kuan-Yu
Hsu, Chin-Wang
Bai, Chyi-Huey
Chen, Chiehfeng
Hsu, Yuan-Pin
Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title_full Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title_fullStr Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title_full_unstemmed Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title_short Intranasal lidocaine for acute migraine: A meta-analysis of randomized controlled trials
title_sort intranasal lidocaine for acute migraine: a meta-analysis of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808552/
https://www.ncbi.nlm.nih.gov/pubmed/31644605
http://dx.doi.org/10.1371/journal.pone.0224285
work_keys_str_mv AT chipeiwen intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT hsiehkunyi intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT chenkuanyu intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT hsuchinwang intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT baichyihuey intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT chenchiehfeng intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials
AT hsuyuanpin intranasallidocaineforacutemigraineametaanalysisofrandomizedcontrolledtrials